Peptides are short chains of amino acids (typically 2–50) that act as signaling molecules in the body, influencing everything from hormone regulation and tissue repair to metabolism and immune function. As building blocks of proteins, they offer high specificity, potent bioactivity, and often favorable safety profiles compared to traditional small-molecule drugs or larger biologics. In recent years, peptide therapeutics have exploded in popularity and research, with over 80 approved peptide drugs contributing billions in revenue and more than 150 candidates in clinical trials as of 2025.

The global peptide and protein therapeutics market continues to expand rapidly, driven by advances in synthesis, delivery, and design that overcome historical challenges like poor stability and bioavailability. A 2025 review in Acta Pharmaceutica Sinica B highlights how peptide-based treatments provide realized and potential benefits due to their targeted action and reduced off-target effects. Another comprehensive overview in Signal Transduction and Targeted Therapy (2025) emphasizes progress in peptide drugs, delivery platforms, and vaccines for conditions like diabetes, obesity, oncology, and rare diseases.

Here are some key categories of therapeutic peptides and their evidence-based benefits:

1. GLP-1 Receptor Agonists for Weight Loss and Metabolic Health

Peptides like semaglutide (e.g., Ozempic, Wegovy) and tirzepatide (e.g., Mounjaro, Zepbound) mimic gut hormones to regulate appetite, insulin, and glucose.

• Semaglutide vs. Tirzepatide: A 2024 JAMA Internal Medicine study of real-world data showed tirzepatide led to greater weight loss than semaglutide in adults with overweight/obesity (average reductions favoring tirzepatide).
• Head-to-Head Trial: A 2025 NEJM phase 3b trial confirmed tirzepatide’s superiority, with participants losing ~20.2% body weight vs. ~13.7% on semaglutide over 72 weeks, plus better waist circumference reductions.
• Real-World Outcomes: A 2025 JMIR study of a remote program reported mean 12-month weight loss of ~22.1% with tirzepatide and ~17.1% with semaglutide, with high proportions achieving ≥10–15% reductions and improved behaviors like increased activity.

These peptides are FDA-approved for obesity and type 2 diabetes, with strong evidence for sustained fat loss, metabolic improvements, and reduced cardiovascular risk.

(Images: Before-and-after conceptual illustrations of body composition changes with GLP-1 therapies; molecular structure of semaglutide or tirzepatide; graph showing percentage weight loss from clinical trials.)

2. Growth Hormone-Releasing Peptides (e.g., CJC-1295 and Ipamorelin)

These stimulate natural GH and IGF-1 release, supporting muscle maintenance, recovery, fat metabolism, and vitality.

• CJC-1295: A 2006 randomized trial in healthy adults showed subcutaneous CJC-1295 caused dose-dependent, sustained increases in GH (2–10-fold for 6+ days) and IGF-1 (1.5–3-fold for 9–11 days), with a half-life of ~6–8 days and good tolerability.
• Combination with Ipamorelin: The duo produces synergistic GH pulses, with Ipamorelin offering selective, short bursts. While direct body composition trials in healthy adults are limited, elevated GH/IGF-1 links to improved lean mass, fat oxidation, and recovery in related research.

These are often used off-label for anti-aging or performance, though evidence is stronger for GH-deficient states.

3. Regenerative and Healing Peptides (e.g., BPC-157 and Thymosin Beta-4/TB-500)

These promote tissue repair, angiogenesis, and anti-inflammation.

• BPC-157: Derived from gastric juice, preclinical (animal) studies show accelerated healing in muscle, tendon, ligament, and bone injuries via growth factor pathways and reduced inflammation. A 2025 systematic review noted improved functional and biomechanical outcomes in models, with one small retrospective human study reporting pain relief in 7/12 chronic knee pain patients after intra-articular injection (>6 months in responders). Safety appears favorable in animals (no toxicity at wide doses), but human clinical data remain limited (e.g., a Phase I trial assessed pharmacokinetics/safety in volunteers, with rapid clearance). No large RCTs confirm efficacy or long-term safety in humans.
• Thymosin Beta-4 (TB-500): Promotes cell migration, angiogenesis, and wound healing while reducing fibrosis. Preclinical models (e.g., dermal wounds in rats/mice) show accelerated repair. Small Phase 2 human trials for stasis/pressure ulcers reported faster healing (up to a month earlier in responders) and reduced scar formation.

These show promise in regenerative contexts but lack robust human trials for most claims.

Safety and Considerations

Peptides generally offer high specificity and low toxicity in studies, but challenges include short half-lives (addressed via modifications like cyclization or lipidation) and delivery barriers. Approved ones (e.g., semaglutide, tirzepatide) have strong safety data from large trials, while research/experimental peptides (e.g., BPC-157) carry risks from unregulated sources or unknown long-term effects.

Always consult a qualified healthcare provider for personalized assessment, as peptides should be used under supervision.

At Tri-Health Wellness Centre, Dr. Jason Granzotto ND and the team stay informed on emerging peptide research to guide patients toward safe, integrative options—often combined with naturopathic tools like nutrition, InBody analysis, or IV therapies.

Curious about peptides for recovery, metabolism, or longevity? Book a consultation to discuss what might fit your goals.

Call Tri-Health Wellness Centre at (905) 605-WELL (9355) or book online via our Jane App. Located in Woodbridge (Vaughan), we’re here to support evidence-informed wellness—naturally!

What sparked your interest in peptides—recovery, weight management, or something else? Share below—we’d love to hear! 🌿